Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)
dc.contributor.author | Meyer, T | |
dc.contributor.author | Finn, R | |
dc.contributor.author | Kudo, M | |
dc.contributor.author | Kang, Y | |
dc.contributor.author | Yen, C | |
dc.contributor.author | Galle, P | |
dc.contributor.author | Llovet, J | |
dc.contributor.author | Assenat, E | |
dc.contributor.author | Brandi, G | |
dc.contributor.author | Motomura, K | |
dc.contributor.author | Okusaka, T | |
dc.contributor.author | Hubner, Richard A | |
dc.contributor.author | Karwal, M | |
dc.contributor.author | Baron, A | |
dc.contributor.author | Ikeda, M | |
dc.contributor.author | Liang, K | |
dc.contributor.author | Wang, C | |
dc.contributor.author | Widau, R | |
dc.contributor.author | Schelman, W | |
dc.contributor.author | Zhu, A | |
dc.date.accessioned | 2020-03-27T09:28:03Z | |
dc.date.available | 2020-03-27T09:28:03Z | |
dc.date.issued | 2019 | en |
dc.identifier.citation | Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, et al. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019;30 Suppl 4:iv133. | en |
dc.identifier.pmid | 32085038 | en |
dc.identifier.doi | 10.1093/annonc/mdz154.020 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622839 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1093/annonc/mdz154.020 | en |
dc.title | Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Royal Free Hospital, University College London, London, UK | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-03-30T14:03:38Z |